tradingkey.logo

J&J JNJ-5939 Was Well Tolerated In Phase 2B Duplex-Ad Proof-Of-Concept Study

ReutersDec 26, 2025 1:08 PM

- Johnson & Johnson JNJ.N:

  • J&J: JNJ-5939 WAS WELL TOLERATED IN PHASE 2B DUPLEX-AD PROOF-OF-CONCEPT STUDY

  • J&J: JNJ-5939 MET PRESPECIFIED CRITERIA FOR EARLY TERMINATION OF THE STUDY

Source text: [ID:]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI